---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013608"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:24:59.258203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances

## Summary
- Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
- Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.
- LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.
- LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.
- withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO.

## SEC filing metadata
- accession: 0001493152-26-013608
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013608
- JSON: https://secwatch.observer/filing/0001493152-26-013608.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013608.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.
  - Period: the fiscal year and fourth quarter ended December 31, 2025
  - Result: reported results
  source text: On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.